Loading data for CVKD — first visit, this takes a few seconds.
Cadrenal Therapeutics Inc... (CVKD)
NasdaqCM: CVKD
· Real-Time Price · USD
1.54
-0.02 (-1.28%)
At close: Aug 28, 2026, 3:59 PM
1.55
+0.65%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Cadrenal Therapeutics Inc. (CVKD) Stock Price, Analysis & Data
-1.28% (1D)
| Bid | 1.54 |
| Market Cap | 5.49M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.54M |
| 1.86 | |
| -4.8 | |
| n/a | |
| -0.45 | |
| P/B (ttm) | 1.17 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 1.6 |
| Volume | 31,153 |
| Avg. Volume (20D) | 68,133 |
| Open | 1.56 |
| Previous Close | 1.56 |
| Day's Range | 1.50 - 1.60 |
| 52-Week Range | 1.49 - 14.64 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CVKD
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 20, 2023
Employees 5
Stock Exchange NasdaqCM
Ticker Symbol CVKD
Website https://www.cadrenal.com
Financial Performance
In 2025, Cadrenal Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -13.24M, an increase of 24.28%.
Financial StatementsEarnings Surprise
Cadrenal Therapeutics has released their quarterly earnings on Aug 13, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -1.14 misses estimates by -0.19, with 39.04% YoY growth.
